

Veltuzumab

| | |
|-----------|-------------------------------------------------------------------------------------------|
| Cat. No.: | HY-P99224 |
| CAS No.: | 728917-18-8 |
| Target: | Integrin |
| Pathway: | Cytoskeleton |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |

BIOLOGICAL ACTIVITY

| | | |
|---------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|
| Description | Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody. Veltuzumab has low EC ₅₀ value of 0.08-0.09 µg/mL in the Daudi cell line. Veltuzumab can be used for the research of cancer including non-Hodgkin lymphoma (NHL) ^[1] . | |
| IC ₅₀ & Target | EC ₅₀ : 0.08-0.09 µg/mL (in the Daudi cell line) ^[1] | |
| In Vitro | Veltuzumab significantly reduces off-rates in human lymphoma cell lines, as well as increases complement-dependent cytotoxicity in 1 of 3 cell lines, but no other in vitro differences ^[1] . | |
| | Veltuzumab (0.001-10 µg/mL, 3 h) has low EC ₅₀ value of 0.08-0.09 µg/mL in the Daudi cell line ^[1] . | |
| | MCE has not independently confirmed the accuracy of these methods. They are for reference only. | |
| | Cell Cytotoxicity Assay ^[1] | |
| | Cell Line: | 4 lymphoma cell lines (SU-DHL-6, Daudi, Raji and WSU-FSCCL) |
| In Vivo | Concentration: | 5 µg/mL |
| | Incubation Time: | 4 days |
| | Result: | Had the sensitivity correlated with CD20 expression (SU-DHL6> Raji > Daudi > WSU-FSCCL). |
| | Veltuzumab (i.v. or s.c.; 5, 20 and 60 µg; single) can control tumor growth or deplete circulating or sessile B cells at low doses in mouse models of intraperitoneal and subcutaneous doses ^[1] . | |
| | Veltuzumab (i.p.; 0.05-35 µg) are significantly effective in vivo ^[1] . | |
| | MCE has not independently confirmed the accuracy of these methods. They are for reference only. | |
| | Animal Model: | Lymphoma xenograft model ^[1] |
| | Dosage: | 5, 20 and 60 µg |
| | Administration: | intraperitoneal and subcutaneous, single |
| | Result: | Showed low dose of 0.05 µg increased the MST. |

| | |
|-----------------|--------------------------------------------------------|
| Animal Model: | SCID mice ^[1] |
| Dosage: | 0.5, 0.25, 0.1, or 0.05 µg; 35, 3.5, 0.35, or 0.035 µg |
| Administration: | intraperitoneal, single |
| Result: | Improved significantly survival. |

REFERENCES

[1]. David M Goldenberg, et al. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA